FUJIFILM Diosynth Biotechnologies vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison

How does FUJIFILM Diosynth Biotechnologies compare to Merck KGaA / MilliporeSigma (CDMO)?

As of Aug 2026, FUJIFILM Diosynth Biotechnologies: no FDA inspections on file, 35 EMA/MHRA GMP certificates. Signal Score 86.7. Merck KGaA / MilliporeSigma (CDMO): 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 81.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
87/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
29
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Darmstadt, DE · St. Louis, MO
Signal Score
82/100
Quality (FDA + GMP)
99/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
22
Capacity
—
Modalities
mRNA, Biologics, Cell Therapy

Key differences

  • Merck KGaA / MilliporeSigma (CDMO) has FDA inspections on record (2); FUJIFILM Diosynth Biotechnologies does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (29 active certificates vs 2) — stronger EU footprint.
  • FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; Merck KGaA / MilliporeSigma (CDMO) does not.
  • Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.

Across the cross-modality scorecard, FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: FUJIFILM Diosynth Biotechnologies vs Merck KGaA / MilliporeSigma (CDMO)

How does FUJIFILM Diosynth Biotechnologies compare to Merck KGaA / MilliporeSigma (CDMO)?

On CDMO Signal's composite Signal Score, FUJIFILM Diosynth Biotechnologies is 87/100 and Merck KGaA / MilliporeSigma (CDMO) is 82/100; FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record vs 2 for Merck KGaA / MilliporeSigma (CDMO); European coverage is 35 active EMA+MHRA certificates for FUJIFILM Diosynth Biotechnologies vs 2 for Merck KGaA / MilliporeSigma (CDMO). Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, FUJIFILM Diosynth Biotechnologies or Merck KGaA / MilliporeSigma (CDMO)?

Both FUJIFILM Diosynth Biotechnologies and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record; Merck KGaA / MilliporeSigma (CDMO) has 2.

How do FUJIFILM Diosynth Biotechnologies and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?

FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — FUJIFILM Diosynth Biotechnologies or Merck KGaA / MilliporeSigma (CDMO)?

FUJIFILM Diosynth Biotechnologies is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

FUJIFILM Diosynth Biotechnologies carries a Signal Score of 87/100 and Merck KGaA / MilliporeSigma (CDMO) carries 82/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating FUJIFILM Diosynth Biotechnologies and Merck KGaA / MilliporeSigma (CDMO) for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.